All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Renal Impairment (RI) is a major issue faced by 20–30% of Multiple Myeloma (MM) patients. RI in MM is associated with poor prognosis and an Overall Survival (OS) of less than two years. Due to the impact of RI on the pharmacokinetics of drugs excreted by the kidneys, RI limits treatment options in patients with Relapsed and Refractory MM (RRMM). MM-013 is the first phase II, open-label, noncomparative study to assess the efficacy, renal response, safety, and pharmacokinetics of pomalidomide plus low-dose dexamethasone (LoDEX) in RRMM patients with moderate or severe RI, with the inclusion of patients receiving hemodialysis. The study was conducted by Meletios Dimopoulos, from National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, and colleagues and was published in the Journal of Clinical Oncology in February 2018.
All data is given as cohort A (moderate RI), cohort B (severe RI) and cohort C (severe RI requiring hemodialysis):
All data is given as cohort A (moderate RI), cohort B (severe RI) and cohort C (severe RI requiring hemodialysis):
This study is the first prospective trial to demonstrate that patients with severe RI and high disease burden have a clinically relevant outcome when treated with pomalidomide plus LoDEX. Additionally, this study demonstrated that the recommended dose of pomalidomide 4 mg/d can be safely administered to all patients in these cohorts.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox